Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 283 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Relapsing-remitting Multiple Sclerosis Clear all
Active, not recruiting No phase listed Observational

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05925049
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 22, 2026, 10:47 AM EDT
Recruiting Not applicable Interventional

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

NCT06796504
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Implant Procedure, Disease-Modifying Therapies (DMTs), Active stimulation, Non-active stimulation
Procedure · Drug · Device
Lead sponsor
SetPoint Medical Corporation
Industry
Eligibility
22 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Irvine, California • Atlanta, Georgia • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 22, 2026, 10:47 AM EDT
Recruiting Not applicable Interventional

Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis

NCT06919900
View directory record Official record
Conditions
Multiple Sclerosis (Relapsing Remitting)
Interventions
Perturbation Training, Treadmill Walking
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
45 Years to 89 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

NCT02545868
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
23-PPV, 13-PCV Booster, Influenza Vaccine, KLH, OCR, TT Vaccine
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
20
States / cities
Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 22, 2026, 10:47 AM EDT
Completed No phase listed Observational

Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities

NCT01456416
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT00882999
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
LY2127399, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

NCT02988401
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
Insulin, Placebo (Sterile diluent)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 22, 2026, 10:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study

NCT00937677
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tysabri
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

NCT00559702
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
natalizumab, standard of care
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 22, 2026, 10:47 AM EDT
Terminated Phase 3 Interventional Results available

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT01578785
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Glatiramer Acetate, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
25
States / cities
Cullman, Alabama • Fresno, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Light Therapy as Treatment for Fatigue in Multiple Sclerosis

NCT03060759
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Light Therapy box
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 22, 2026, 10:47 AM EDT
Terminated No phase listed Observational

Adherence Trial With MS LifeLines ® Services

NCT01905527
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B
Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

An Extension of the TG1101-RMS201 Trial

NCT03381170
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Ublituximab
Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Pasadena, California • Aurora, Colorado • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects

NCT05181215
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Monomethyl Fumarate 190 Mg, Diroximel Fumarate 462 mg
Drug
Lead sponsor
Banner Life Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 22, 2026, 10:47 AM EDT
Recruiting Not applicable Interventional

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions
Acute Intermittent Hypoxia, Sham-Acute Intermittent Hypoxia
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

NCT00340834
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
35
States / cities
Cullman, Alabama • Phoenix, Arizona • Oceanside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 22, 2026, 10:47 AM EDT
Withdrawn Phase 2 Interventional

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

NCT00986960
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
repository corticotropin injection, Saline
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 22, 2026, 10:47 AM EDT
Completed No phase listed Observational

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron

NCT00461396
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon-1beta (Betaseron, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Many Locations, Alabama • Many Locations, Arizona • Many Locations, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2011 · Synced Oct 22, 2026, 10:47 AM EDT
Active, not recruiting Phase 4 Interventional

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

NCT05090371
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Ofatumumab, Disease modifying treatment (DMT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Birmingham, Alabama • Cullman, Alabama • Chandler, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Not applicable Interventional

Wahls Paleo Diet and Progressive Multiple Sclerosis

NCT01915433
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Wahls Paleo Plus, Wahls Diet
Other
Lead sponsor
Terry L. Wahls
Other
Eligibility
30 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

NCT02634307
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ALKS 8700
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
74
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

NCT01067521
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Glatiramer acetate (GA), Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)

NCT02258217
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Acthar
Drug
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

NCT00451451
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BG00012, Placebo, Glatiramer Acetate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
72
States / cities
Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 22, 2026, 10:47 AM EDT